JW Therapeutics

Market position

The company positions itself as an independent innovator in China's cell immunotherapy sector and states an aim to lead the healthy and standardized development of that industry. Presenting RELIANCE trial results, it described the study as the first demonstration of licensure-quality CAR-T manufacturing and clinical trial data generation in relapsed/refractory patients originating in China, with relma-cel showing comparable preliminary response rates and PK to, and potential for an improved toxicity profile versus, other CD19-directed CAR-Ts approved in the US and EU.

The company emphasizes a comprehensive and differentiated pipeline spanning hematological cancers and solid tumors, including allogeneic approaches, small-molecule combination strategies and CAR-T products with new gene modifications, and cites clinical evidence suggesting relma-cel may offer an improved toxicity profile relative to other approved CD19 CAR-Ts while achieving similar preliminary response rates.

Technology

Core technology is chimeric antigen receptor T-cell (CAR-T) therapy, beginning with the CD19-directed candidate JWCAR029 (relmacabtagene autoleucel). The company describes an integrated cell immunotherapy platform covering discovery, process development, GMP manufacturing and quality management, including in-house lentiviral vector production, and states its pipeline includes next-generation approaches such as allogeneic cell therapies, combinations with small molecules, CAR-T products with new gene modifications, and TCR-T programs (including a MAGE-A4 TCR-T program).

Go-to-market

Products are delivered through hospitals that complete company-run training and certification for administering 瑞基奥仑赛注射液; the company also maintains regulatory filings for its medical representatives in China and pursues payer listings and regulatory expansions into additional indications and jurisdictions.

Patients in China and beyond with hematologic malignancies (notably relapsed/refractory large B-cell lymphoma / DLBCL), solid tumors and autoimmune diseases such as systemic lupus erythematosus and systemic sclerosis, treated at hospitals certified to administer the company's CAR-T products.

Geography

Headquartered in Shanghai, China, with products marketed in mainland China and approval obtained in Macao; the company states ambitions for patients in China and globally and presents data at international conferences in the US and Europe.

History

JW Therapeutics was established in 2016 by Juno Therapeutics and WuXi AppTec Group. By 2018 it had initiated clinical development of its first CD19-directed CAR-T candidate, JWCAR029, had an IND accepted by the China Food and Drug Administration, and had built a validated clinical GMP facility; that year it closed a US$90 million Series A round. Its CAR-T product 瑞基奥仑赛注射液 (Carteyva®/倍诺达®) was approved for marketing by China's NMPA, with the company publishing a list of trained and certified treating institutions dated 1 September 2021. Subsequent milestones disclosed in company press releases include a breakthrough therapy designation in China for Carteyva® as second-line treatment in relapsed/refractory adult large B-cell lymphoma (January 2025), an sLVV license agreement with Juno Therapeutics (April 2025), NMPA acceptance of a supplemental biologics license application for second-line use (May 2025), marketing approval in Macao (June 2025), first patient infusion in a JWCAR239 study (September 2025), NMPA acceptance of a post-marketing supplemental application using an in-house produced lentiviral vector (October 2025), an expanded strategic collaboration with Regeneron on TCR-T cell therapy (October 2025), and inclusion of Carteyva® in the first edition of the National Healthcare Security Administration's commercial health insurance innovative drug directory (December 2025).